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Will High-Sensitivity Troponin Improve the Evaluation of
Patients With Chest Pain in the Emergency Department?*


































cApproximately 8 million people in the United
States are evaluated for chest pain in the emergency
department (ED) each year at an estimated cost of
over $10 billion (1,2). Most of these individuals do
not have an acute coronary syndrome (ACS). How-
ever, atypical symptoms of myocardial ischemia are
common in certain patient subsets, and the initial
electrocardiogram (ECG) is often normal or non-
specific. In patients with a missed diagnosis of
ACS, the mortality rate is increased (3), and mal-
practice expenses are high (4). Therefore the tradi-
tional approach has been to admit most of these
patients. In an attempt to develop more efficient
and less costly practice models, many institutions
See page 72
have implemented the chest pain unit. The stan-
dard protocol consists of serial measurements over
several hours of the ECG and biomarkers, usually
troponin (Tn) I or T, followed by stress testing with
or without echocardiographic or nuclear imaging
(1). Computed tomographic angiography (CTA) is
also being investigated for its potential role in this
setting (2,5). Although the chest pain unit approach
can reduce unnecessary hospital admissions, patient
evaluation is time-consuming and labor-intensive,
contributing to overcrowding and lengthy stays in
the ED.
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the contents of this paper to disclose.Given these issues, there is tremendous appeal in
dentifying a biomarker that could be easily mea-
ured early in the ED evaluation that would provide
ccurate diagnosis and risk stratification. Troponin
s the preferred biomarker for diagnosing acute
yocardial infarction (6). Current Tn assays have
igh clinical sensitivity but nonetheless can only
etect Tn values in the nanogram/milliliter range
normal 0.01 ng/ml). A new generation of “high-
ensitivity” Tn (hsTn) assays are more sensitive by
n order of magnitude, with values reported in the
icogram/milliliter range (7–9).
In this issue of iJACC, Ahmed et al. (10) evaluated
he association between hsTnT and both abnormal
yocardial perfusion measured by single photon
mission computed tomography (SPECT) and the
xtent of coronary artery disease (CAD) measured by
TA in a subset of 138 patients enrolled in the
OMICAT I (Rule Out Myocardial Infarction using
omputer Assisted Tomography) trial (5). The
sTnT levels were significantly different between pa-
ients with normal versus abnormal SPECT: median
alues 4.89 pg/ml versus 9.41 pg/ml (p  0.001). At
sTnT levels in the range of 4 to 6 pg/ml, sensitivity
o detect abnormal SPECT was 80% to 90%, and
egative predictive value was 96%. The discriminatory
bility of hsTnT to predict abnormal SPECT assessed
y receiver-operating characteristic curve analysis re-
orted area under the curve of 0.739. The hsTnT
evels were significantly correlated with the SPECT
schemia score (r2  0.15, p  0.0001) and CTA
laque burden (r2  0.08, p  0.0004).
These findings are intriguing, but the reader
hould be aware of several limitations when inter-
reting the results of this study. First, the study
roup was small and highly selected. Exclusion
riteria for the ROMICAT I trial included new

























J A C C : C A R D I O V A S C U L A R I M A G I N G , V O L . 6 , N O . 1 , 2 0 1 3
J A N U A R Y 2 0 1 3 : 8 3 – 5
Miller and Bailey
Editorial Comment
84marker, serum creatinine 1.3 mg/dl, or history of
CAD revascularization (5). These criteria contrib-
uted to recruiting a low-risk population for the
current study with mean age of 54 years, 54%
female, and 82% Thrombolysis In Myocardial In-
farction score 0 to 1. The results of this study might
not be generalizable to other ED populations,
which characteristically include older patients with
more comorbidities, many of whom have estab-
lished CAD. Second, hsTnT was measured at a
single time point. The authors provide only the
median time (4.2 h) but not the time range. The
hsTnT measured at 4 h after presentation might
not provide the same information as a measurement
at 2 h or 6 h, even in the same patient. Serial
measurements likely reflect optimal performance of
the assay (7,9). Third, 19 patients (14%) had
abnormal SPECT, but only 10 of these patients had
ischemia. The distinction between ischemic and
fixed SPECT defects is clinically important, but the
authors did not test for differences in hsTnT be-
tween these patient subsets. Only 7 of the 19
patients (37%) with abnormal SPECT had a sig-
nificant stenosis (50% diameter narrowing) by
CTA or invasive angiography. What is the etiology
of the “perfusion defect” in the other 12 patients?
The authors suggest that these defects could be
caused by plaque rupture in an insignificant stenosis
with downstream embolization (Fig. 5 in Ahmed et
al. [10]) but offer no proof for this concept. Of note,
mean body mass index of the population was 30 
6 kg/m2, and attenuation correction was not applied
or processing the SPECT images. Some of the
erfusion defects might have represented attenua-
ion artifacts, posing a challenge to explain a statis-
ically significant association between hsTnT levels
nd the SPECT findings. Fourth, Ahmed et al.
10) analyzed the utility of hsTnT cut-points be-
ween 4.26 to 8.62 pg/ml for targeted sensitivities
etween 60% and 90% (Table 2). Inspection of
igure 1 in Ahmed et al. (10) reveals that these
ubstantial differences in sensitivity thresholds are
ased on only a handful of data points crossing a
arrow range of hsTnT cut-points. The findings
ould be more robust if based upon more data
oints. Fifth, the receiver-operating characteristic
urve (Fig. 2 in Ahmed et al. [10]) reveals only fair
perating characteristics for hsTnT, which mighterformance of additional testing to be cost-
ffective. Sixth, Figure 3 in Ahmed et al. demon-
trates statistically significant associations between
og-transformed hsTnT and SPECT summed dif-
erence score and CTA coronary segments with
laque, but the correlation coefficients are weak
r2  0.15 and 0.08, respectively). Most of the data
points line up along the y  0 axis. The slope of the
curve for the SPECT ischemia analysis is heavily
influenced by 2 extreme data points in the northeast
quadrant of the graph. Seventh, potentially interesting
and useful information is not included in the manu-
script. The authors allude to the performance of
invasive angiography in some patients, but the number
of these patients is not provided. The agreement
between stenosis number and severity detected by
CTA and invasive angiography is not stated. For
discrepant results, the authors do not specify which
result they selected for their statistical analyses. The
original ROMICAT trial (5) reported outcome end-
points. Comparing the prognostic accuracy of hsTnT,
SPECT, and CTA could provide insight substantiat-
ing the clinical value of these measurements.
Despite these limitations Ahmed et al. (10) have
provided an important first step in evaluating hsTnT
against conventional imaging modalities commonly
applied in the ED. High-sensitivity TnT will detect
more CAD than conventional Tn assays. Although
Tn assays have high analytic specificity, an elevated
Tn does not have high clinical specificity for the
clinical scenario of plaque rupture (type I) myocardial
infarction (6). A negative hsTnT will be highly
reassuring for ruling out myocardial necrosis and
might eliminate the need for subsequent testing in
some patients, but a potential concern is that
hsTnT will be commonly elevated in clinical sce-
narios not associated with ACS and lead to addi-
tional and possibly unnecessary testing in other
patients. More robust data are needed to support
the statement of the authors that hsTnT might
serve as a “powerful triage tool.” The correct
application and interpretation of hsTn in the ED
will require obtaining greater clinical experience
using these assays in larger and broader patient
populations.
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